Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Thromboembolic potential of different anti-CD40L antibody formats in a comparative 8-week study in Rhesus monkeys

From: CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study

Dose group (n) Total animals affected (%) Total affected lung sections Total examined lung sections Lung sections affected (%)
Historic saline controls 7 (50) 10 406 2.5
(n = 14)a
Concurrent saline control 1 (25) 1 116 0.9
(n = 2/sex)a
CDP7657 3 (37.5) 4 232 (203)c 1.7 (2.0)c
(n = 4/sex)b
Aglycosyl hu5c8 3 (37.5) 3 232 1.3
(n = 4/sex)
Hu5c8 5 (62.5) 41 232 17.6
(n = 4/sex)
  1. Thrombembolic events were defined as the occurrence of thrombus, an organizing thrombus or intimal hyperplasia. aHistoric control group of Rhesus monkeys that had received i.v. saline for up to 6 months; bone animal died on day 2, which was unrelated to CDP7657 treatment; cvalues in parentheses do not include animals removed from the study for humane reasons unrelated to the study